Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 10
Submit an article Journal homepage
360
Views
10
CrossRef citations to date
0
Altmetric
Original Articles

Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine

Maria TsirogianniDepartment of Hematology and Bone Marrow Transplantation, Saint Savvas Regional Cancer Hospital, Athens, Greece; View further author information
,
Eirini GrigoriouDepartment of Immunology and Histocompatibility, “Evangelismos” General Hospital, Athens, Greece;View further author information
,
Violetta KapsimalliDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece;View further author information
,
Kleopatra DaglaHematology Division, 2nd Department of Internal Medicine, “ATTIKO” General University Hospital, National and Kapodistrian University of Athens, Athens, Greece;View further author information
,
Maria StamouliHematology Division, 2nd Department of Internal Medicine, “ATTIKO” General University Hospital, National and Kapodistrian University of Athens, Athens, Greece;View further author information
,
Konstantinos GkirkasHematology Division, 2nd Department of Internal Medicine, “ATTIKO” General University Hospital, National and Kapodistrian University of Athens, Athens, Greece;View further author information
,
Eve KonstaHematology Division, 2nd Department of Internal Medicine, “ATTIKO” General University Hospital, National and Kapodistrian University of Athens, Athens, Greece;View further author information
,
Angeliki KaragiannidouHematology Division, 2nd Department of Internal Medicine, “ATTIKO” General University Hospital, National and Kapodistrian University of Athens, Athens, Greece;View further author information
,
Konstantinos GkodopoulosHematology Division, 2nd Department of Internal Medicine, “ATTIKO” General University Hospital, National and Kapodistrian University of Athens, Athens, Greece;View further author information
,
Georgia StavroulakiHematology Division, 2nd Department of Internal Medicine, “ATTIKO” General University Hospital, National and Kapodistrian University of Athens, Athens, Greece;View further author information
,
Vassiliki PappaHematology Division, 2nd Department of Internal Medicine, “ATTIKO” General University Hospital, National and Kapodistrian University of Athens, Athens, Greece;View further author information
,
Maria AngelopoulouDepartment of Hematology and Bone Marrow Transplantation, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece; View further author information
,
Mark LowdellInstitute of Immunity and Transplantation Centre for Cell, Gene & Tissue Therapeutics, Royal Free Hospital, London, UKView further author information
&
Panagiotis TsirigotisHematology Division, 2nd Department of Internal Medicine, “ATTIKO” General University Hospital, National and Kapodistrian University of Athens, Athens, Greece;Correspondence[email protected]
View further author information
 show all
Pages 2457-2463 | Received 03 Dec 2018, Accepted 03 Feb 2019, Published online: 05 Apr 2019

References

  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–569.
  • Gao X, Lin J, Wang L, et al. Demethylating treatment suppresses natural killer cell cytolytic activity. Mol Immunol. 2009;46:2064–2070.
  • Tsirigotis P, Resnick IB, Shapira MY. The role of natural killer cells in hematopoietic stem cell transplantation. Ann Med. 2012;44:130–145.
  • Lowdell MW, Craston R, Samuel D, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol. 2002;117:821–827.
  • Tsirigotis P, Resnick IB, Kapsimalli V, et al. Irradiated mononuclear cells express significant in vitro cytotoxic activity: promise for in vivo clinical efficacy of irradiated mismatched donor lymphocytes infusion. Immunotherapy. 2014;6:409–417.
  • Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.
  • Fazekas de St Groth B, Zhu E, et al. Flow cytometric detection of human regulatory T cells. Methods Mol Biol. 2011;707:263–279.
  • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
  • Cheson B, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425.
  • Hejazi M, Manser AR, Fröbel J, et al. Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes. Haematologica. 2015;100:643–652.
  • Kiladjian JJ, Bourgeois E, Lobe I, et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia. 2006;20:463–470.
  • Epling-Burnette PK, Bai F, Painter JS, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007;109:4816–4824.
  • Carlsten M, Baumann BC, Simonsson M, et al. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD341 blasts in myelodysplastic syndrome. Leukemia. 2010;24:1607–1616.
  • Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166:678–689.
  • Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. 2013;123:4595–4611.
  • Gleason MK, Ross JA, Warlick ED, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 2014;123:3016–3026.
  • Jiang HJ, Fu R, Wang HG, et al. Increased circulating of myeloid-derived suppressor cells in myelodysplastic syndrome. Chin Med J. 2013;126:2582–2584.
  • Chaudhary B, Abd Al Samid M, al-Ramadi BK, et al. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opin Biol Ther. 2014;14:931–945.
  • Kordasti SY, Ingram W, Hayden J, et al. CD4 + CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood. 2007;110:847–850.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.